Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Ipilimumab is a standard therapy for advanced melanoma. Severe immune related adverse events occur in up to 30% of patients and require treatment with immunosuppressants such as steroids or the anti-TNFα antibody, infliximab. We describe two patients with advanced melanoma treated with ipilimumab. Both suffered from severe immune related side effects and required prolonged immunosuppression with steroids and/or infliximab. Both patients recovered and in spite of the immune suppression, demonstrate clinical evidence of tumor control. This argues that distinct immunological effector functions control nosocomial infection and tumor, respectively. To our knowledge, these are also the first two case reports of pneumocystis pneumonia in this setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624 · cited 1×
“The main concern when using immunosuppressants is the potential adverse effect on tumor immune control, leading to worse clinical outcome, although this seems not to be the case for low-dose steroid treatment.(5) A second concern is that iatrogenic immune suppression may increase the risk of opportunistic infections.”
BackgroundIpilimumab and Its Toxicities: A Multidisciplinary Approach
Fecher, L. A., Agarwala, S. S., Hodi, F. S., & Weber, J. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0483 · Cited by 320 · cited 1×
“When these irAEs are severe or persistent, the recommended treatment is the use of steroids in the first line instance and, when this is insufficient, the administration of potent immunosuppressants such as infliximab (anti-TNFa).(4) The main concern when using immunosuppressants is the potential adverse effect on tum…”
Background
Cited by
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Del Castillo, M., Romero, F. A., Argüello, E., Kyi, C., Postow, M. A., & Redelman-Sidi, G. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw539 · Cited by 294
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1962-6 · Cited by 234
Subudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611421113 · Cited by 226
“Although most irAEs induced by immune checkpoint therapies can be reversed with high-dose steroids and/or other immunosuppressive therapies, prolonged immunosuppression can have severe consequences, including acquisition of life-threatening opportunistic infections (24, 25).”
BackgroundMolecular Pathways: Immune Checkpoint Antibodies and their Toxicities
Cousin, S., & Italiano, A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2569 · Cited by 83
Metadata
- Authors
- Arriola, E., Wheater, M., Krishnan, R., Smart, J., Foria, V., & Ottensmeier, C.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2015-08-28
- Volume
- 4
- Issue
- 10
- Pages
- e1040218
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W1898612748
- Cited by
- 45
- References
- 2
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control. https://app.cochat.ai/papers/10.1080/2162402x.2015.1040218
- The paper
- Arriola, E., Wheater, M., Krishnan, R., Smart, J., Foria, V., & Ottensmeier, C. (2015). Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control. OncoImmunology. https://doi.org/10.1080/2162402x.2015.1040218
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.